244 related articles for article (PubMed ID: 25213022)
21. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
[TBL] [Abstract][Full Text] [Related]
22. Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer.
Quan D; Chen K; Zhang J; Guan Y; Yang D; Wu H; Wu S; Lv L
J Cell Physiol; 2020 Apr; 235(4):3372-3381. PubMed ID: 31621912
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
[TBL] [Abstract][Full Text] [Related]
26. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK
Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256
[TBL] [Abstract][Full Text] [Related]
27. CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
Fang Z; Lin A; Chen J; Zhang X; Liu H; Li H; Hu Y; Zhang X; Zhang J; Qiu L; Mei L; Shao J; Chen X
Oncotarget; 2016 Nov; 7(47):78055-78068. PubMed ID: 27801665
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y
Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119
[TBL] [Abstract][Full Text] [Related]
29. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
30. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
31. Potential mechanism of RRM2 for promoting Cervical Cancer based on weighted gene co-expression network analysis.
Wang J; Yi Y; Chen Y; Xiong Y; Zhang W
Int J Med Sci; 2020; 17(15):2362-2372. PubMed ID: 32922202
[TBL] [Abstract][Full Text] [Related]
32. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
33. High RRM2 expression has poor prognosis in specific types of breast cancer.
Shi SC; Zhang Y; Wang T
PLoS One; 2022; 17(3):e0265195. PubMed ID: 35290409
[TBL] [Abstract][Full Text] [Related]
34. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Wilson EA; Sultana N; Shah KN; Elford HL; Faridi JS
Mol Cancer Ther; 2021 Apr; 20(4):655-664. PubMed ID: 33536192
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Yang PM; Lin LS; Liu TP
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
[TBL] [Abstract][Full Text] [Related]
36. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
37. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Su YF; Wu TF; Ko JL; Tsai HT; Tee YT; Chien MH; Chou CH; Lin WL; Low HY; Chou MY; Yang SF; Wang PH
PLoS One; 2014; 9(3):e91644. PubMed ID: 24637958
[TBL] [Abstract][Full Text] [Related]
38. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
Yau C; Benz CC
Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
[TBL] [Abstract][Full Text] [Related]
39. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
[TBL] [Abstract][Full Text] [Related]
40. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
